Other

Chugai Seiyaku Kabushiki Kaisha

Kyowa Hakko Kogyo Co., Ltd.

Fujisawa Pharmaceutical Company, Ltd.

Kyowa Hakko Kirin Co., Limited

Helix Research Institute

Astellas Pharma Gmbh

Yamanouchi Pharmaceutical Company Ltd.

Japan As Represented by President of National Cancer Center

Research Association for Biotechnology

Toshio Ota

Takao Isogai

Tetsuo Nishikawa

Akiko Furuya

Koji Hayashi

Tomoyasu Sugiyama

Sumio Sugano

Kenji Shibata

Yusuke Nakamura

Yuki Kobayashi

Keiichi Nagai

Susumu Sekine

Mitsuo Satoh

Kazuya Yamano

Shin-Ichi Funahashi

Ai Wakamatsu

Tetsuji Otsuki

Shoji Miyata

Kaoru Otsuka

Jun-Ichi Yamamoto

Shizuko Ishii

Kenji Sobue

Miho Takebayashi

Yuri Kawai

Jun Takasaki

Susumu Satoh

Masazumi Kamohara

Mitsuyuki Matsumoto

Tetsu Saito

Yuri Hio

Hiroyuki Arakawa

Mayako Yamazaki

Masahiko Morita

Tohru Sugimoto

Kenya Shitara

Emi Hosaka

Atsushi Ochiai

Hiromasa Miyaji

So Ohta

Yuka Sasaki

Norihiko Shiraishi

Yoko Kato

Hiroyuki Nagata

Ayako Kawabata

Susume Sekine

Motoko Haruoka

A cDNA fragment participating in the maintenance of smooth muscle differentiation was isolated using a culture system of chicken gizzard smooth muscle cells, the differential display method and the subtracted hybridization method. Using the obtained cDNA sequence as a query, cDNA sequences of Helix Research Institute (Japanese Patent Application No. 2000-118776) were retrieved, and thus, a novel gene 'C-NT2RP3001495' was obtained. The protein encoded by this gene has two WW domains that participate in protein interactions in the N-terminal domain. Evidence suggests that this protein binds to other proteins, and thus regulates the intracellular signal transduction, gene expression, and so on, thereby participating in the maintenance of the differentiation of smooth muscle cells. This protein and compounds regulating the expression thereof are markedly useful in developing drugs for various diseases associated with abnormality in the maintenance of smooth muscle cell differentiation.

Antibody directed to protein involved in maintaining differentiation of smooth muscle cells

The present invention provides an antibody which specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by PERP (p53 apoptosis effector related to PMP-22) gene and binds to the extracellular region. The antibody of the present invention is useful for treatment of various diseases which highly expresses a polypeptide encoded by the PERP gene. Also, a polypeptide encoded by the PERP gene or a cell expressing the polypeptide can be specifically detected by an immunological method using the antibody, so that the antibody is useful for diagnosis of various diseases related to PERP.

Anti-perp antibody

Using the proteins of the present invention, DNAs encoding the proteins, and antibodies recognizing the proteins, detection methods for diseases relating to the novel insulin-like growth factor binding proteins of the present invention, as well as diagnostic agents, preventive agents, and therapeutic agents for diseases relating to the proteins of the present invention can be provided.

Antibodies to insulin-like growth factor binding protein and uses thereof

Insulin-like growth factor binding protein

Genes associated with the maintenance of differentiation of smooth muscle cells

The present invention relates to a novel phospholipase Apolypeptide, DNA encoding the polypeptide, a vector comprising the DNA, a transformant transformed with the vector, and a process for producing the phospholipase Apolypeptide. The present invention also relates to a method of utilizing the polypeptide, e.g., a method of screening for a compound having agonist or antagonist activity by using the polypeptide or an antibody to the polypeptide, and a pharmaceutical comprising the polypeptide or an antibody to the polypeptide. The present invention further relates to a polypeptide inhibiting the phospholipase Aactivity of a phospholipase Apolypeptide (hereinafter referred to as inhibitor polypeptide), DNA encoding the inhibitor polypeptide, a vector comprising the DNA encoding the inhibitor polypeptide, a transformant transformed with the vector, a pharmaceutical comprising the inhibitor polypeptide, and a process for producing the inhibitor polypeptide.

[object Object]

A cDNA encoding a novel LTCreceptor has been isolated. Provision of the novel protein, an LTCreceptor, enabled binding experiments using the LTC. By screening for compounds that modulate LTCreceptor activity based on these binding experiments, development of drugs targeting the LTCreceptor becomes possible.

Peptide leukotriene receptor

Human cDNA encoding a secretory or membrane protein useful as a candidate for developing medicine or as a target molecule for developing medicine. The expression level of the polynucleotide of the present invention increased in NT2 cells after retinoic acid-treatment. Accordingly, this cDNA is associated neurological disease.

Secretory protein or membrane protein

Insulin-like growth factor-binding protein

The present invention provides: proteins suppressing or promoting the aggregation or deposition of amyloid-&#x3b2; protein; polynucleotides encoding the proteins; a method for screening a compound suppressing or promoting the aggregation or deposition of amyloid-&#x3b2; protein; and therapeutic agents for treating or preventing Alzheimer's diseases comprising a compound that regulates the activity of a protein suppressing or promoting the aggregation or deposition of amyloid-&#x3b2; protein.

Amyloid-&#x3b2; protein aggregation-regulating factors

Amyloid &#x3b2; protein agglutination-controlling factor

Growing community of inventors

Tokyo, Japan

Toshio Ota